Mifamurtide Acid

Summary

Mifamurtide Acid (CHEMBL2111100) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 4
• Chemistry: 1237.5 Da · C59H109N6O19P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2111100
Name	Mifamurtide Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	11672602
Molecular formula	C59H109N6O19P
Molecular weight	1237.5
InChIKey	JMUHBNWAORSSBD-WKYWBUFDSA-N

SMILES: CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(=O)N)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@@H]([C@H](OC([C@@H]1NC(=O)C)O)CO)O)OC(=O)CCCCCCCCCCCCCCC

IUPAC name: [(2R)-3-[2-[[(2S)-2-[[(4R)-4-[[(2S)-2-[[(2R)-2-[(3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoyl]amino]ethoxy-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] hexadecanoate

Also known as: CGP-19835, Mifamurtide acid, Mifamurtide free acid anhydrous, mifamurtide

Parent form; salt/anhydrous children: CHEMBL2107354

Patent coverage: 1,329 distinct patent families (3,383 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Estrogen receptor, Progesterone receptor.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ESR1	5.31	AC50	4901	nM	CHEMBL_ACT_25138624
PGR	5.06	AC50	8635	nM	CHEMBL_ACT_25204057

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE2	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03643133	PHASE2	ACTIVE_NOT_RECRUITING	Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients
NCT02441309	PHASE2	TERMINATED	A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)
NCT00631631	Not specified	COMPLETED	Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma
NCT01194284	Not specified	TERMINATED	Surveillance Study of Patients With Newly Diagnosed Osteosarcoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).